APO Research
Talk to an analyst

APO RESEARCH · REPORT

GFP Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GFP Antibody Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchGFP Antibody Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal GFP Antibody Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal GFP Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GFP Antibody Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal GFP Antibody Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global GFP Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GFP Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GFP Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GFP Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GFP Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GFP Antibody market include Thermo Fisher Scientific, United States Biological, Synaptic Systems, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents, Miltenyi Biotec and Medimabs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global GFP Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GFP Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GFP Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global GFP Antibody market.

GFP Antibody Segment by Company

Thermo Fisher Scientific

United States Biological

Synaptic Systems

Santa Cruz Biotechnology

Proteintech

ProSci

NSJ Bioreagents

Miltenyi Biotec

Medimabs

EXBIO

Bio X Cell

Aviva Systems Biology

GFP Antibody Segment by Type

Polyclonal

Monoclonal

GFP Antibody Segment by Application

Immunohistochemistry

Immunofluorescence

Immunocytochemistry

Western Blot

Others

GFP Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global GFP Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the GFP Antibody key companies, revenue, market share, and recent developments.

3. To split the GFP Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions GFP Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GFP Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze GFP Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GFP Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GFP Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GFP Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GFP Antibody industry.

Chapter 3: Detailed analysis of GFP Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of GFP Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of GFP Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GFP Antibody Industry Trends Table 2. GFP Antibody Industry Drivers Table 3. GFP Antibody Industry Opportunities and Challenges Table 4. GFP Antibody Industry Restraints Table 5. Global GFP Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GFP Antibody Revenue Share by Company (2021-2026) Table 7. Global GFP Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global GFP Antibody Key Company Manufacturing Base & Headquarters Table 9. Global GFP Antibody Company, Product Type & Application Table 10. Global GFP Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global GFP Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global GFP Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global GFP Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global GFP Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global GFP Antibody Sales Value Share by Type (2021-2026) Table 20. Global GFP Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Table 22. Significant Companies of Immunofluorescence Table 23. Significant Companies of Immunocytochemistry Table 24. Significant Companies of Western Blot Table 25. Significant Companies of Others Table 26. Global GFP Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global GFP Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global GFP Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global GFP Antibody Sales Value Share by Application (2021-2026) Table 30. Global GFP Antibody Sales Value Share by Application (2027-2032) Table 31. Global GFP Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global GFP Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global GFP Antibody Sales Value Share by Region (2021-2026) Table 34. Global GFP Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global GFP Antibody Sales Value Share by Region (2027-2032) Table 36. Global GFP Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global GFP Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global GFP Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global GFP Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global GFP Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific GFP Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. United States Biological Company Information Table 47. United States Biological Business Overview Table 48. United States Biological GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. United States Biological GFP Antibody Product Portfolio Table 50. United States Biological Recent Development Table 51. Synaptic Systems Company Information Table 52. Synaptic Systems Business Overview Table 53. Synaptic Systems GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Synaptic Systems GFP Antibody Product Portfolio Table 55. Synaptic Systems Recent Development Table 56. Santa Cruz Biotechnology Company Information Table 57. Santa Cruz Biotechnology Business Overview Table 58. Santa Cruz Biotechnology GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Santa Cruz Biotechnology GFP Antibody Product Portfolio Table 60. Santa Cruz Biotechnology Recent Development Table 61. Proteintech Company Information Table 62. Proteintech Business Overview Table 63. Proteintech GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Proteintech GFP Antibody Product Portfolio Table 65. Proteintech Recent Development Table 66. ProSci Company Information Table 67. ProSci Business Overview Table 68. ProSci GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ProSci GFP Antibody Product Portfolio Table 70. ProSci Recent Development Table 71. NSJ Bioreagents Company Information Table 72. NSJ Bioreagents Business Overview Table 73. NSJ Bioreagents GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. NSJ Bioreagents GFP Antibody Product Portfolio Table 75. NSJ Bioreagents Recent Development Table 76. Miltenyi Biotec Company Information Table 77. Miltenyi Biotec Business Overview Table 78. Miltenyi Biotec GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Miltenyi Biotec GFP Antibody Product Portfolio Table 80. Miltenyi Biotec Recent Development Table 81. Medimabs Company Information Table 82. Medimabs Business Overview Table 83. Medimabs GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Medimabs GFP Antibody Product Portfolio Table 85. Medimabs Recent Development Table 86. EXBIO Company Information Table 87. EXBIO Business Overview Table 88. EXBIO GFP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. EXBIO GFP Antibody Product Portfolio Table 90. EXBIO Recent Development Table 91. Bio X Cell Company Information Table 92. Bio X Cell Business Overview Table 93. Bio X Cell GFP Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bio X Cell GFP Antibody Product Portfolio Table 95. Bio X Cell Recent Development Table 96. Aviva Systems Biology Company Information Table 97. Aviva Systems Biology Business Overview Table 98. Aviva Systems Biology GFP Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Aviva Systems Biology GFP Antibody Product Portfolio Table 100. Aviva Systems Biology Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. GFP Antibody Product Image Figure 2. Global GFP Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GFP Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global GFP Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global GFP Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global GFP Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global GFP Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Image Figure 13. Immunofluorescence Image Figure 14. Immunocytochemistry Image Figure 15. Western Blot Image Figure 16. Others Image Figure 17. Global GFP Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global GFP Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global GFP Antibody Sales Value Share by Application (2021-2032) Figure 20. Global GFP Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global GFP Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America GFP Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America GFP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe GFP Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe GFP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific GFP Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific GFP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America GFP Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America GFP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa GFP Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa GFP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt GFP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt GFP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt GFP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry
  • Immunofluorescence
  • Immunocytochemistry
  • Western Blot
  • Others
Companies covered
  • Thermo Fisher Scientific
  • United States Biological
  • Synaptic Systems
  • Santa Cruz Biotechnology
  • Proteintech
  • ProSci
  • NSJ Bioreagents
  • Miltenyi Biotec
  • Medimabs
  • EXBIO
  • Bio X Cell
  • Aviva Systems Biology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GFP Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GFP Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 GFP Antibody Market Dynamics
  1. 2.1 GFP Antibody Industry Trends
  2. 2.2 GFP Antibody Industry Drivers
  3. 2.3 GFP Antibody Industry Opportunities and Challenges
  4. 2.4 GFP Antibody Industry Restraints
3 GFP Antibody Market by Company
  1. 3.1 Global GFP Antibody Company Revenue Ranking in 2025
  2. 3.2 Global GFP Antibody Revenue by Company (2021-2026)
  3. 3.3 Global GFP Antibody Company Ranking (2024-2026)
  4. 3.4 Global GFP Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global GFP Antibody Company Product Type and Application
  6. 3.6 Global GFP Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global GFP Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 GFP Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 GFP Antibody Market by Type
  1. 4.1 GFP Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global GFP Antibody Sales Value by Type
  5. 4.2.1 Global GFP Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GFP Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global GFP Antibody Sales Value Share by Type (2021-2032)
5 GFP Antibody Market by Application
  1. 5.1 GFP Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry
  3. 5.1.2 Immunofluorescence
  4. 5.1.3 Immunocytochemistry
  5. 5.1.4 Western Blot
  6. 5.1.5 Others
  7. 5.2 Global GFP Antibody Sales Value by Application
  8. 5.2.1 Global GFP Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global GFP Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global GFP Antibody Sales Value Share by Application (2021-2032)
6 GFP Antibody Regional Value Analysis
  1. 6.1 Global GFP Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GFP Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global GFP Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global GFP Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GFP Antibody Sales Value (2021-2032)
  7. 6.3.2 North America GFP Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe GFP Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe GFP Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific GFP Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific GFP Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America GFP Antibody Sales Value (2021-2032)
  16. 6.6.2 South America GFP Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa GFP Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa GFP Antibody Sales Value Share by Country, 2025 VS 2032
7 GFP Antibody Country-level Value Analysis
  1. 7.1 Global GFP Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GFP Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global GFP Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global GFP Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA GFP Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA GFP Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA GFP Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada GFP Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada GFP Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada GFP Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico GFP Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico GFP Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico GFP Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany GFP Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany GFP Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany GFP Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France GFP Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France GFP Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France GFP Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. GFP Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. GFP Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. GFP Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy GFP Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy GFP Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy GFP Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain GFP Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain GFP Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain GFP Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia GFP Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia GFP Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia GFP Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands GFP Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands GFP Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands GFP Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries GFP Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries GFP Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries GFP Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China GFP Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China GFP Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China GFP Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan GFP Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan GFP Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan GFP Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea GFP Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea GFP Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea GFP Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India GFP Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India GFP Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India GFP Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia GFP Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia GFP Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia GFP Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia GFP Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia GFP Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia GFP Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil GFP Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil GFP Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil GFP Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina GFP Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina GFP Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina GFP Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile GFP Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile GFP Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile GFP Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia GFP Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia GFP Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia GFP Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru GFP Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru GFP Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru GFP Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia GFP Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia GFP Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia GFP Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel GFP Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel GFP Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel GFP Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE GFP Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE GFP Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE GFP Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey GFP Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey GFP Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey GFP Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran GFP Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran GFP Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran GFP Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt GFP Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt GFP Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt GFP Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific GFP Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific GFP Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 United States Biological
  8. 8.2.1 United States Biological Company Information
  9. 8.2.2 United States Biological Business Overview
  10. 8.2.3 United States Biological GFP Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 United States Biological GFP Antibody Product Portfolio
  12. 8.2.5 United States Biological Recent Developments
  13. 8.3 Synaptic Systems
  14. 8.3.1 Synaptic Systems Company Information
  15. 8.3.2 Synaptic Systems Business Overview
  16. 8.3.3 Synaptic Systems GFP Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Synaptic Systems GFP Antibody Product Portfolio
  18. 8.3.5 Synaptic Systems Recent Developments
  19. 8.4 Santa Cruz Biotechnology
  20. 8.4.1 Santa Cruz Biotechnology Company Information
  21. 8.4.2 Santa Cruz Biotechnology Business Overview
  22. 8.4.3 Santa Cruz Biotechnology GFP Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santa Cruz Biotechnology GFP Antibody Product Portfolio
  24. 8.4.5 Santa Cruz Biotechnology Recent Developments
  25. 8.5 Proteintech
  26. 8.5.1 Proteintech Company Information
  27. 8.5.2 Proteintech Business Overview
  28. 8.5.3 Proteintech GFP Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Proteintech GFP Antibody Product Portfolio
  30. 8.5.5 Proteintech Recent Developments
  31. 8.6 ProSci
  32. 8.6.1 ProSci Company Information
  33. 8.6.2 ProSci Business Overview
  34. 8.6.3 ProSci GFP Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProSci GFP Antibody Product Portfolio
  36. 8.6.5 ProSci Recent Developments
  37. 8.7 NSJ Bioreagents
  38. 8.7.1 NSJ Bioreagents Company Information
  39. 8.7.2 NSJ Bioreagents Business Overview
  40. 8.7.3 NSJ Bioreagents GFP Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NSJ Bioreagents GFP Antibody Product Portfolio
  42. 8.7.5 NSJ Bioreagents Recent Developments
  43. 8.8 Miltenyi Biotec
  44. 8.8.1 Miltenyi Biotec Company Information
  45. 8.8.2 Miltenyi Biotec Business Overview
  46. 8.8.3 Miltenyi Biotec GFP Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Miltenyi Biotec GFP Antibody Product Portfolio
  48. 8.8.5 Miltenyi Biotec Recent Developments
  49. 8.9 Medimabs
  50. 8.9.1 Medimabs Company Information
  51. 8.9.2 Medimabs Business Overview
  52. 8.9.3 Medimabs GFP Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medimabs GFP Antibody Product Portfolio
  54. 8.9.5 Medimabs Recent Developments
  55. 8.10 EXBIO
  56. 8.10.1 EXBIO Company Information
  57. 8.10.2 EXBIO Business Overview
  58. 8.10.3 EXBIO GFP Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 EXBIO GFP Antibody Product Portfolio
  60. 8.10.5 EXBIO Recent Developments
  61. 8.11 Bio X Cell
  62. 8.11.1 Bio X Cell Company Information
  63. 8.11.2 Bio X Cell Business Overview
  64. 8.11.3 Bio X Cell GFP Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bio X Cell GFP Antibody Product Portfolio
  66. 8.11.5 Bio X Cell Recent Developments
  67. 8.12 Aviva Systems Biology
  68. 8.12.1 Aviva Systems Biology Company Information
  69. 8.12.2 Aviva Systems Biology Business Overview
  70. 8.12.3 Aviva Systems Biology GFP Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aviva Systems Biology GFP Antibody Product Portfolio
  72. 8.12.5 Aviva Systems Biology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst